BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Silva MF, Wigg AJ. Current controversies surrounding liver transplantation for hepatocellular carcinoma. J Gastroenterol Hepatol. 2010;25:1217-1226. [PMID: 20594247 DOI: 10.1111/j.1440-1746.2010.06335.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Hsu C, Hsia C, Huang Y, Su C, Lin H, Chiou Y, Lee R, Lee F, Huo T, Lee S. Differential prognostic impact of renal insufficiency on patients with hepatocellular carcinoma: A propensity score analysis and staging strategy: Impact of renal insufficiency. Journal of Gastroenterology and Hepatology 2012;27:690-9. [DOI: 10.1111/j.1440-1746.2011.06886.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
2 Wang YL, Zhu ZJ, Teng DH, Yao Z, Gao W, Shen ZY. Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation. World J Gastroenterol 2012; 18(19): 2408-2414 [PMID: 22654434 DOI: 10.3748/wjg.v18.i19.2408] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
3 Azzam AZ. Liver transplantation as a management of hepatocellular carcinoma. World J Hepatol 2015; 7(10): 1347-1354 [PMID: 26052380 DOI: 10.4254/wjh.v7.i10.1347] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
4 Kornberg A, Küpper B, Tannapfel A, Büchler P, Krause B, Witt U, Gottschild D, Friess H. Patients with non-[18 F]fludeoxyglucose-avid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation. Liver Transpl. 2012;18:53-61. [PMID: 21850692 DOI: 10.1002/lt.22416] [Cited by in Crossref: 60] [Cited by in F6Publishing: 63] [Article Influence: 6.0] [Reference Citation Analysis]
5 Hu Z, Zhou J, Li Z, Xiang J, Qian Z, Wu J, Zhang M, Zheng S. Time interval to recurrence as a predictor of overall survival in salvage liver transplantation for patients with hepatocellular carcinoma associated with hepatitis B virus. Surgery 2015;157:239-48. [PMID: 25616940 DOI: 10.1016/j.surg.2014.09.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lee JY, Kim YH, Yi NJ, Kim HS, Lee HS, Lee BK, Kim H, Choi YR, Hong G, Lee KW. Impact of immunosuppressant therapy on early recurrence of hepatocellular carcinoma after liver transplantation. Clin Mol Hepatol. 2014;20:192-203. [PMID: 25032186 DOI: 10.3350/cmh.2014.20.2.192] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
7 Végső G, Görög D, Fehérvári I, Nemes B, Doros A, Langer RM, Kóbori L. Role of Organ Transplantation in the Treatment of Malignancies – Hepatocellular Carcinoma as the Most Common Tumour Treated with Transplantation. Pathol Oncol Res 2012;18:1-10. [DOI: 10.1007/s12253-011-9441-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
8 Seehofer D, Öllinger R, Denecke T, Schmelzle M, Andreou A, Schott E, Pratschke J. Blood Transfusions and Tumor Biopsy May Increase HCC Recurrence Rates after Liver Transplantation. J Transplant 2017;2017:9731095. [PMID: 28154760 DOI: 10.1155/2017/9731095] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
9 Lee SD, Kim SH, Kim SK, Kim YK, Park SJ. Clinical Impact of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma. Transplantation. 2015;99:2142-2149. [PMID: 25905981 DOI: 10.1097/tp.0000000000000719] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
10 Gao T, Xia Q, Qiu DK, Feng YY, Chi JC, Wang SY, Xi ZF, Zhang JJ, Xu N, Chen SY. Comparison of survival and tumor recurrence rates in patients undergoing liver transplantation for hepatitis B-related hepatocellular carcinoma using Milan, Shanghai Fudan and Hangzhou criteria. J Dig Dis. 2013;14:552-558. [PMID: 23782458 DOI: 10.1111/1751-2980.12083] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
11 Çelebi F, Görmez A, Serkan Ilgun A, Tokat Y, Cem Balcı N. The role of 18F- FDG PET/MRI in preoperative prediction of MVI in patients with HCC. European Journal of Radiology 2022. [DOI: 10.1016/j.ejrad.2022.110196] [Reference Citation Analysis]
12 . Current world literature. Curr Opin Organ Transplant 2011;16:338-41. [PMID: 21562392 DOI: 10.1097/MOT.0b013e3283473baa] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
13 Fischer SE. Recurrent and de novo malignancies following liver transplantation. Diagnostic Histopathology 2012;18:290-6. [DOI: 10.1016/j.mpdhp.2012.07.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
14 Guerrini GP, Pinelli D, Marini E, Corno V, Guizzetti M, Zambelli M, Aluffi A, Lincini L, Fagiuoli S, Lucianetti A, Colledan M. Value of HCC-MELD Score in Patients With Hepatocellular Carcinoma Undergoing Liver Transplantation. Prog Transplant 2018;28:63-9. [PMID: 29251164 DOI: 10.1177/1526924817746686] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]